应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
01681 康臣药业
开市前 09-20 09:26:51
6.050
+0.020
+0.33%
最高
6.050
最低
6.050
成交量
6,000
今开
6.050
昨收
6.030
日振幅
0.00%
总市值
51.12亿
流通市值
51.12亿
总股本
8.45亿
成交额
3.63万
换手率
0.00%
流通股本
8.45亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
康臣药业09月16日主力资金流入331万元 连续3日加仓
市场透视 · 09-16
康臣药业09月16日主力资金流入331万元 连续3日加仓
康臣药业(01681):中期股息记录日期将更改为9月9日
智通财经 · 09-06
康臣药业(01681):中期股息记录日期将更改为9月9日
康臣药业09月04日主力资金流出1041万元 连续3日减仓
市场透视 · 09-04
康臣药业09月04日主力资金流出1041万元 连续3日减仓
康臣药业09月03日遭主力抛售859万元 环比增加246.37%
市场透视 · 09-03
康臣药业09月03日遭主力抛售859万元 环比增加246.37%
安信国际 | 康臣药业(1681.HK):利润端增速亮眼,高分红回报股东
安信国际 · 08-28
安信国际 | 康臣药业(1681.HK):利润端增速亮眼,高分红回报股东
营收利润双增、基本面稳健,康臣药业(01681)二级市场价值亟待重估
智通财经 · 08-28
营收利润双增、基本面稳健,康臣药业(01681)二级市场价值亟待重估
【券商聚焦】安信国际维持康臣药业(01681)“增持”评级 指其分红水平位于行业前列
金吾财讯 · 08-27
【券商聚焦】安信国际维持康臣药业(01681)“增持”评级 指其分红水平位于行业前列
康臣药业08月23日主力资金流入5万元 连续3日加仓
市场透视 · 08-23
康臣药业08月23日主力资金流入5万元 连续3日加仓
【券商聚焦】中邮证券维持康臣药业(01681)“买入”评级 称上半年集采以量换价取得成效 下半年有望延续增长态势
金吾资讯 · 08-23
【券商聚焦】中邮证券维持康臣药业(01681)“买入”评级 称上半年集采以量换价取得成效 下半年有望延续增长态势
康臣药业(01681)24H1归母净利润增长约15%,24年股息率有望超10%
信达证券 · 08-22
康臣药业(01681)24H1归母净利润增长约15%,24年股息率有望超10%
康臣药业(01681):高海恩获任公司秘书及授权代表
智通财经 · 08-22
康臣药业(01681):高海恩获任公司秘书及授权代表
康臣药业(01681.HK):高海恩获委任为公司秘书及授权代表
格隆汇资讯 · 08-22
康臣药业(01681.HK):高海恩获委任为公司秘书及授权代表
港股异动 | 康臣药业绩后大涨超8% 中期纯利同比增14.9% 派息翻倍
格隆汇 · 08-21
港股异动 | 康臣药业绩后大涨超8% 中期纯利同比增14.9% 派息翻倍
康臣药业:中期业绩亮眼 收入增长 13.3%
和讯网 · 08-21
康臣药业:中期业绩亮眼 收入增长 13.3%
港股异动 | 康臣药业(01681)绩后涨超6% 上半年纯利升14.9%至4亿元人民币 中期息0.3港元
智通财经 · 08-21
港股异动 | 康臣药业(01681)绩后涨超6% 上半年纯利升14.9%至4亿元人民币 中期息0.3港元
异动解读 | 康臣药业半年净利增长14.9% 多条产品线销售亮眼 股价应声大涨
异动解读 · 08-21
异动解读 | 康臣药业半年净利增长14.9% 多条产品线销售亮眼 股价应声大涨
康臣药业将于9月20日派发中期股息每股0.3港元
新浪港股 · 08-21
康臣药业将于9月20日派发中期股息每股0.3港元
康臣药业发布中期业绩 股东应占溢利约4亿元同比增加约14.9%
新浪港股 · 08-21
康臣药业发布中期业绩 股东应占溢利约4亿元同比增加约14.9%
康臣药业(01681)上涨5.17%,报5.9元/股
金融界 · 08-21
康臣药业(01681)上涨5.17%,报5.9元/股
康臣药业盘中异动 大幅拉升5.17%报5.901港元
自选股智能写手 · 08-21
康臣药业盘中异动 大幅拉升5.17%报5.901港元
加载更多
公司概况
公司名称:
康臣药业
所属市场:
SEHK
上市日期:
--
主营业务:
康臣药业集团有限公司是一家投资控股公司,主要从事生产和销售药品业务。该公司的药品包括肾病药物、对比剂及其他。该公司的子公司包括智达集团有限公司、世纪国际拓展有限公司和宏致有限公司。该公司通过其子公司还从事研发药品业务。
发行价格:
--
{"stockData":{"symbol":"01681","market":"HK","secType":"STK","nameCN":"康臣药业","latestPrice":6.05,"timestamp":1726795246005,"preClose":6.03,"halted":0,"volume":6000,"delay":0,"floatShares":844889255,"shares":844889255,"eps":1.0938388,"marketStatus":"开市前","marketStatusCode":1,"change":0.02,"latestTime":"09-20 09:26:51","open":6.05,"high":6.05,"low":6.05,"amount":36300,"amplitude":0,"askPrice":6.08,"askSize":6000,"bidPrice":6.05,"bidSize":9000,"shortable":3,"etf":0,"ttmEps":1.1420687380163808,"exchange":"SEHK","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1726795800000},"adr":0,"adjPreClose":6.03,"dividendRate":0.099982,"openAndCloseTimeList":[[1726795800000,1726804800000],[1726808400000,1726819200000]],"volumeRatio":0,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01681","defaultTab":"news","newsList":[{"id":"2467894923","title":"康臣药业09月16日主力资金流入331万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2467894923","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467894923?lang=zh_cn&edition=full","pubTime":"2024-09-16 16:16","pubTimestamp":1726474574,"startTime":"0","endTime":"0","summary":"09月16日, 康臣药业股价涨1.88%,报收5.95元,成交金额3747万元,换手率0.76%,振幅5.14%,量比1.11。康臣药业今日主力资金净流入331万元,连续3日净流入,上一交易日主力净流入229万元,今日环比增加44.54%。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为20.00%,平均涨幅为0.18%。该股近5个交易日上涨5.68%,主力资金累计净流出390万元;近20日主力资金累计净流出3072万元,其中净流出天数为10日。该股主力净额占比0.07%,港股市场排名33/2636。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024091616162895687dc1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024091616162895687dc1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01681","BK1606","BK1191"],"gpt_icon":0},{"id":"2465685402","title":"康臣药业(01681):中期股息记录日期将更改为9月9日","url":"https://stock-news.laohu8.com/highlight/detail?id=2465685402","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2465685402?lang=zh_cn&edition=full","pubTime":"2024-09-06 08:31","pubTimestamp":1725582676,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康臣药业(01681)发布公告,中国香港于2024年9月5日(星期四)下午6时20分起悬挂8号台风信号,并预计将至少持续至2024年9月6日(星期五)中午12时正。原定为2024年9月6日(星期五)的记录日期将更改为2024年9月9日(星期一)。因此,为符合资格获中期股息,所有股份过户文件连同相关股票必须于2024年9月9日(星期一)下午4时30分前送达公司的证券登记分处,香港中央证券登记有限公司,地址为中国香港湾仔皇后大道东183 号合和中心17楼1712-1716号铺,办理登记手续。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1180065.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1606","01681"],"gpt_icon":0},{"id":"2464409523","title":"康臣药业09月04日主力资金流出1041万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2464409523","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464409523?lang=zh_cn&edition=full","pubTime":"2024-09-04 16:16","pubTimestamp":1725437789,"startTime":"0","endTime":"0","summary":"09月04日, 康臣药业股价涨0.89%,报收5.67元,成交金额2280万元,换手率0.48%,振幅1.78%,量比0.99。康臣药业今日主力资金净流出1041万元,连续3日净流出,上一交易日主力净流出859万元,今日环比增加21.19%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为42.86%,平均跌幅为2.55%。该股近5个交易日上涨1.07%,主力资金累计净流出2305万元;近20日主力资金累计净流出1986万元,其中净流出天数为7日。该股主力净额占比0.22%,港股市场排名2631/2640。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024090416172795e14c4e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024090416172795e14c4e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01681","BK1191","BK1606"],"gpt_icon":0},{"id":"2464655821","title":"康臣药业09月03日遭主力抛售859万元 环比增加246.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2464655821","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464655821?lang=zh_cn&edition=full","pubTime":"2024-09-03 16:16","pubTimestamp":1725351388,"startTime":"0","endTime":"0","summary":"09月03日,康臣药业股价收平报5.62元,成交金额2191万元,换手率0.46%,振幅1.96%,量比0.94。康臣药业今日主力资金净流出859万元,上一交易日主力净流出248万元,今日环比增加246.37%。该股近5个交易日上涨0.18%,主力资金累计净流出1219万元;近20日主力资金累计净流出856万元,其中净流出天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409031617109edc01ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409031617109edc01ca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1606","BK1191","01681"],"gpt_icon":0},{"id":"2462796721","title":"安信国际 | 康臣药业(1681.HK):利润端增速亮眼,高分红回报股东","url":"https://stock-news.laohu8.com/highlight/detail?id=2462796721","media":"安信国际","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462796721?lang=zh_cn&edition=full","pubTime":"2024-08-28 09:38","pubTimestamp":1724809098,"startTime":"0","endTime":"0","summary":"公司持续高分红回报股东,累计派息超24亿港元,常年派息比例超30%。主要内容业绩稳定增长,利润增速高于收入增速。2024H1公司实现收入和归母净利润分别为12.7亿元和4.0亿元,分别同比增长13.3%和14.9%,主要是靠妇儿和影像板块的拉动。碘克沙醇注射液和碘普罗胺注射液已于2024年7月获批上市,预计2025年开始贡献业绩。持续高额分红,大力回报股东。2024H1公司宣派中期股息每股0.3港元,5月为庆祝上市十周年,宣派特别股息每股0.3港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408280955259f5fff8b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408280955259f5fff8b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1606","01681"],"gpt_icon":0},{"id":"2462782861","title":"营收利润双增、基本面稳健,康臣药业(01681)二级市场价值亟待重估","url":"https://stock-news.laohu8.com/highlight/detail?id=2462782861","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462782861?lang=zh_cn&edition=full","pubTime":"2024-08-28 09:05","pubTimestamp":1724807157,"startTime":"0","endTime":"0","summary":"其中只有22家实现归母净利润同比正增长,行业业绩分化明显。从此次中报来看,康臣药业在面临集采扩面的情况下,依然做到营收和利润双位数增长,说明公司核心肾科领域的先发优势难以撼动。从盘面观察,今年以来,康臣药业明显获得资金青睐,股价涨幅感人。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1172789.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01681"],"gpt_icon":0},{"id":"2462901170","title":"【券商聚焦】安信国际维持康臣药业(01681)“增持”评级 指其分红水平位于行业前列","url":"https://stock-news.laohu8.com/highlight/detail?id=2462901170","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462901170?lang=zh_cn&edition=full","pubTime":"2024-08-27 10:28","pubTimestamp":1724725725,"startTime":"0","endTime":"0","summary":"金吾财讯 | 安信国际发研指,康臣药业 于2024H1实现收入和归母净利润分别为12.7亿元和4.0亿元,分别同比增长13.3%和14.9%,主要是靠妇儿和影像板块的拉动。目前公司已累计派息超24亿港元,派息比例常年超30%,分红水平在行业排前列。该行预计公司2024-2026年收入分别为28.5亿元、31.6亿元和35.4亿元,对应增幅10.0%、10.9%和11.8%,归母净利润分别为8.9亿元、10.1亿元和11.4亿元,对应增幅13.4%、13.6%和12.9%,对应PE分别为4.6x、4.1x和3.6x,维持“增持”评级。","market":"other","thumbnail":"https://static.szfiu.com/news/20200915/MGYzMDMzNGFiY2IxZDI0MzU2YTQ4NTEzZTUyODAwMDc0ODA2MTY2.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200915/MGYzMDMzNGFiY2IxZDI0MzU2YTQ4NTEzZTUyODAwMDc0ODA2MTY2.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1943077","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01681"],"gpt_icon":0},{"id":"2461593015","title":"康臣药业08月23日主力资金流入5万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2461593015","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461593015?lang=zh_cn&edition=full","pubTime":"2024-08-23 16:16","pubTimestamp":1724401003,"startTime":"0","endTime":"0","summary":"08月23日, 康臣药业股价跌4.07%,报收5.66元,成交金额3742万元,换手率0.78%,振幅5.08%,量比0.99。康臣药业今日主力资金净流入5万元,连续3日净流入,上一交易日主力净流入70万元,今日环比减少92.86%。该股近5个交易日上涨0.18%,主力资金累计净流入724万元,其中3个交易日为股价下跌时净流入;近20日主力资金累计净流入1306万元,其中净流入天数为15日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082316175995b753ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082316175995b753ca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1606","BK1191","01681"],"gpt_icon":0},{"id":"2461535061","title":"【券商聚焦】中邮证券维持康臣药业(01681)“买入”评级 称上半年集采以量换价取得成效 下半年有望延续增长态势","url":"https://stock-news.laohu8.com/highlight/detail?id=2461535061","media":"金吾资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461535061?lang=zh_cn&edition=full","pubTime":"2024-08-23 13:43","pubTimestamp":1724391800,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中邮证券发研报指,康臣药业 :2024H1实现营收12.69亿元;实现归母净利润4.00亿元;毛利率74.69%,同比持平;费率管控较好,销售费用率32.47%,管理费用绝对值减少,促进管理费用率下降1.59pct至10.62%;归母净利率31.51%,盈利能力稳健向上。该行续指,2024上半年公司采取了优化授权分管制度、加强临床学术研究力度、升级合规部门设置及改革OTC营销架构等重大举措,由此在集采扩面的形势下实现了以量换价。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082313434195b6c03e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082313434195b6c03e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01681"],"gpt_icon":0},{"id":"2461639589","title":"康臣药业(01681)24H1归母净利润增长约15%,24年股息率有望超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461639589","media":"信达证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461639589?lang=zh_cn&edition=full","pubTime":"2024-08-22 17:17","pubTimestamp":1724318244,"startTime":"0","endTime":"0","summary":"事件:公司发布2024年半年报,2024H1公司实现营业收入12.69亿元,实现归母净利润4亿元,经营活动现金流量净额3.5亿元。②24H1玉林制药分部营收1.6亿元。其他药物销售较去年同期下降约46.9%。24H1净利率略有提升,24年股息率有望超10%:①24H1公司净利率同比提升约0.54个百分点,净利率提升主要系公司期间费用率同比下降约1.05个百分点。若24年末公司不宣派股息,汇总特别股息及中期股息,我们预计24年对应当前市值的股息率为9.95%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408221730329f476ce3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408221730329f476ce3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01681"],"gpt_icon":0},{"id":"2461807262","title":"康臣药业(01681):高海恩获任公司秘书及授权代表","url":"https://stock-news.laohu8.com/highlight/detail?id=2461807262","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461807262?lang=zh_cn&edition=full","pubTime":"2024-08-22 06:49","pubTimestamp":1724280559,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康臣药业(01681)发布公告,丘志明已辞任公司秘书,并不再担任公司授权代表,自2024年8月22日起生效。于丘先生辞任后,高海恩已获委任为公司秘书及授权代表,自2024年8月22日起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1168119.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1606","01681","BK1191"],"gpt_icon":0},{"id":"2461380227","title":"康臣药业(01681.HK):高海恩获委任为公司秘书及授权代表","url":"https://stock-news.laohu8.com/highlight/detail?id=2461380227","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461380227?lang=zh_cn&edition=full","pubTime":"2024-08-22 06:18","pubTimestamp":1724278710,"startTime":"0","endTime":"0","summary":"格隆汇8月22日丨康臣药业(01681.HK)发布公告,丘志明已辞任公司的公司秘书及授权代表,自2024年8月22日起生效。高海恩已获委任为公司秘书及授权代表,自2024年8月22日起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082206183395b19165&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082206183395b19165&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1606","BK1191","01681"],"gpt_icon":0},{"id":"2461997098","title":"港股异动 | 康臣药业绩后大涨超8% 中期纯利同比增14.9% 派息翻倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2461997098","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461997098?lang=zh_cn&edition=full","pubTime":"2024-08-21 13:53","pubTimestamp":1724219582,"startTime":"0","endTime":"0","summary":"格隆汇8月21日|受业绩增长助推,康臣药业(1681.HK)午后开盘直线拉升上扬,现涨超8%报6.08港元,总市值51.4亿港元。 公司午间公布截至今年6月底止中期业绩,营业额12.69亿元,同比增长13.3%;纯利4亿元,同比增长14.9%;派每股中期息0.3港元,上年同期派0.15港元,同比翻倍。 其中尿毒清颗粒仍然是集团的皇牌产品,维持市场领先地位;妇儿系列产品表现亮眼,销售较去年同期增长28.7%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408211353089f40a124&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408211353089f40a124&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1606","01681","BK1191"],"gpt_icon":0},{"id":"2461889268","title":"康臣药业:中期业绩亮眼 收入增长 13.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461889268","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461889268?lang=zh_cn&edition=full","pubTime":"2024-08-21 13:51","pubTimestamp":1724219505,"startTime":"0","endTime":"0","summary":"【康臣药业发布 2024 年中期业绩】康臣药业截至 2024 年 6 月 30 日止六个月,收入 12.69 亿元,同比增长 13.3%。股东应占溢利约 4 亿元,同比增加约 14.9%。每股基本及摊薄盈利分别约 0.4987 元及 0.493 元,拟派中期股息每股 0.3 港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082114245295ad5c3d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082114245295ad5c3d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01681","BK1606","BK1191"],"gpt_icon":0},{"id":"2461993618","title":"港股异动 | 康臣药业(01681)绩后涨超6% 上半年纯利升14.9%至4亿元人民币 中期息0.3港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2461993618","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461993618?lang=zh_cn&edition=full","pubTime":"2024-08-21 13:35","pubTimestamp":1724218513,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,康臣药业绩后涨超6%,截至发稿,涨6.06%,报5.95港元,成交额3803.2万港元。消息面上,康臣药业午间发布截至今年6月底止中期业绩,营业额12.69亿元人民币,同比升13.3%;纯利4亿元,同比升14.9%;派每股中期息0.3港元,上年同期派0.15港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1167514.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01681","BK1191","BK1606"],"gpt_icon":0},{"id":"1107051750","title":"异动解读 | 康臣药业半年净利增长14.9% 多条产品线销售亮眼 股价应声大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=1107051750","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107051750?lang=zh_cn&edition=full","pubTime":"2024-08-21 13:06","pubTimestamp":1724216792,"startTime":"0","endTime":"0","summary":"港股康臣药业8月21日发布上半年业绩,营收和利润均录得两位数增长,多条核心产品线销售实现不俗表现,市场反应热烈,盘中股价一度大涨5.88%。公告显示,今年上半年康臣药业实现营业收入12.69亿元人民币,同比增长13.3%;权益股东应占溢利约4亿元,同比大增14.9%。业绩和产品线的亮眼表现增强了市场对康臣药业长期发展前景的信心。截至发稿,康臣药业报5.901港元/股,大涨5.88%,成交量达280万股,振幅高达6.95%,资金净流入近400万港元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01681"],"gpt_icon":0},{"id":"2461895222","title":"康臣药业将于9月20日派发中期股息每股0.3港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2461895222","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461895222?lang=zh_cn&edition=full","pubTime":"2024-08-21 13:05","pubTimestamp":1724216735,"startTime":"0","endTime":"0","summary":"康臣药业(01681)发布公告,该公司将于2024年9月20日派发中期股息每股0.3港元。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-08-21/doc-inckkqse2706299.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-08-21/doc-inckkqse2706299.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1606","01681","BK1191"],"gpt_icon":0},{"id":"2461489522","title":"康臣药业发布中期业绩 股东应占溢利约4亿元同比增加约14.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461489522","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461489522?lang=zh_cn&edition=full","pubTime":"2024-08-21 13:04","pubTimestamp":1724216671,"startTime":"0","endTime":"0","summary":"康臣药业(01681)发布截至2024年6月30日止六个月中期业绩,收入12.69亿元(人民币,下同),同比增长13.3%;股东应占溢利约4亿元,同比增加约14.9%;每股基本及摊薄盈利分别约0.4987元及0.493元;拟派中期股息每股0.3港元。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-08-21/doc-inckkqsf9471112.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-08-21/doc-inckkqsf9471112.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1606","BK1191","01681"],"gpt_icon":0},{"id":"2461952578","title":"康臣药业(01681)上涨5.17%,报5.9元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2461952578","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461952578?lang=zh_cn&edition=full","pubTime":"2024-08-21 13:01","pubTimestamp":1724216470,"startTime":"0","endTime":"0","summary":"8月21日,康臣药业(01681)盘中上涨5.17%,截至13:01,报5.9元/股,成交1603.64万元。康臣药业集团是一家制药企业,以研发、生产和营销肾科、影像、妇儿、骨伤、皮肤、肝胆、消化系列药品为主要业务,拥有138个品种药品,其中33个品种进入国家基本药物目录,67个品种进入国家医保目录。康臣药业的关键经营数据表现在其当下拥有广东广州、内蒙古通辽、广西玉林、新疆霍尔果斯等4个生产基地,员工逾3000人,且其分销网络遍布全国,业绩长期保持稳定高速增长。截至2023年年报,康臣药业营业总收入25.9亿元、净利润7.85亿元。8月21日,康臣药业披露2024财年中报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/08/21130142554435.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1191","BK1606","01681"],"gpt_icon":0},{"id":"2461895939","title":"康臣药业盘中异动 大幅拉升5.17%报5.901港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2461895939","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461895939?lang=zh_cn&edition=full","pubTime":"2024-08-21 13:01","pubTimestamp":1724216463,"startTime":"0","endTime":"0","summary":"2024年08月21日下午盘13时01分,康臣药业股票出现波动,股价快速上涨5.17%。截至发稿,该股报5.901港元/股,成交量280万股,换手率0.33%,振幅6.95%。康臣药业股票所在的药品行业中,整体涨幅为0.19%。该信息摘要如下:康臣药业8月21日在港交所公告,上半年收入为12.69亿元,同比增加约13.3%;公司权益股东应占溢利约为4亿元,同比增加约14.9%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082113010398e35a2e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082113010398e35a2e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1606","BK1191","01681"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.chinaconsun.com","stockEarnings":[{"period":"1week","weight":0.0598},{"period":"1month","weight":0.135},{"period":"3month","weight":0.1682},{"period":"6month","weight":0.196},{"period":"1year","weight":0.404},{"period":"ytd","weight":0.4718}],"compareEarnings":[{"period":"1week","weight":0.0448},{"period":"1month","weight":0.0287},{"period":"3month","weight":-0.0009},{"period":"6month","weight":0.0917},{"period":"1year","weight":0.0071},{"period":"ytd","weight":0.0567}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康臣药业集团有限公司是一家投资控股公司,主要从事生产和销售药品业务。该公司的药品包括肾病药物、对比剂及其他。该公司的子公司包括智达集团有限公司、世纪国际拓展有限公司和宏致有限公司。该公司通过其子公司还从事研发药品业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.042666},{"month":2,"riseRate":0.545455,"avgChangeRate":0.018798},{"month":3,"riseRate":0.454545,"avgChangeRate":0.013031},{"month":4,"riseRate":0.727273,"avgChangeRate":0.072362},{"month":5,"riseRate":0.545455,"avgChangeRate":0.025395},{"month":6,"riseRate":0.363636,"avgChangeRate":-0.005424},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.031185},{"month":8,"riseRate":0.545455,"avgChangeRate":0.006611},{"month":9,"riseRate":0.545455,"avgChangeRate":-0.003012},{"month":10,"riseRate":0.3,"avgChangeRate":-0.035331},{"month":11,"riseRate":0.6,"avgChangeRate":0.013963},{"month":12,"riseRate":0.5,"avgChangeRate":0.0194}],"exchange":"SEHK","name":"康臣药业","nameEN":"CONSUN PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.4","shortVersion":"4.26.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康臣药业(01681)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康臣药业(01681)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康臣药业,01681,康臣药业股票,康臣药业股票老虎,康臣药业股票老虎国际,康臣药业行情,康臣药业股票行情,康臣药业股价,康臣药业股市,康臣药业股票价格,康臣药业股票交易,康臣药业股票购买,康臣药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康臣药业(01681)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康臣药业(01681)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}